EX-99.1 2 ex_512857.htm EXHIBIT 99.1 ex_512857.htm

Exhibit 99.1

 

picture1.jpg

1245 Q Street, Lincoln, NE 68508

P: 1 800 388 4264 | F: 402 475 9061
nrchealth.com

 

Contact:

Kevin R. Karas

Chief Financial Officer

402-475-2525

 

 

NATIONAL RESEARCH CORPORATION ANNOUNCES

FIRST QUARTER 2023 RESULTS

 


 

LINCOLN, Nebraska (May 2, 2023) — National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2023.

 

Regarding the Company’s 2023 first quarter, Kevin Karas, Chief Financial Officer, said, “We remain focused on enabling healthcare organizations to deliver personalized care, including the recent announcement of MyView to integrate patient insights directly into the EHR to support care teams in understanding the unique and individual needs of the patients they serve. We are further expanding our sales and marketing resources in support of increased awareness and adoption of the Human Understanding Program to benefit both the patients being served and front-line caregivers.”

 

The Company’s Board of Directors maintained its capital allocation priorities of funding innovation and growth investments, including merger and acquisition activity, as well as internal projects, shareholder dividends and share repurchases during 2023. In the first quarter of 2023, the Company funded $2.9 million for innovation and growth, $3.0 million for dividend payments, and $2.0 million for share repurchases.

 

Diluted earnings per share decreased to $0.28 for the quarter ended March 31, 2023, from diluted earnings per share of $0.34 for the quarter ended March 31, 2022.

 

 

NRC Announces First Quarter 2023 Results

Page 2

May 2, 2023

 

A live simulcast of National Research Corporation’s 2023 first quarter conference call will be available online at https://events.q4inc.com/attendee/253347934 May 3, 2023, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.

 

For more than 40 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health’s patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. For more information, email info@nrchealth.com, or visit www.nrchealth.com.

 

This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as believes, expect, derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2022 and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.

 

 

NRC Announces First Quarter 2023 Results

Page 3

May 2, 2023

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

Unaudited Condensed Consolidated Statements of Income

(In thousands, except per share data)

 

   

Three months ended
March 31,

 
   

2023

   

2022

 
                 

Revenue

  $ 36,473     $ 38,441  
                 

Operating expenses:

               

Direct

    14,280       14,779  

Selling, general and administrative

    11,783       10,649  

Depreciation and amortization

    1,394       1,316  

Total operating expenses

    27,457       26,744  
                 

Operating income

    9,016       11,697  
                 

Other income (expense):

               

Interest income

    250       5  

Interest expense

    (241 )     (317 )

Other, net

    (14 )     48  
                 

Total other income (expense)

    (5 )     (264 )
                 

Income before income taxes

    9,011       11,433  
                 

Income tax provision

    2,047       2,894  
                 

Net income

  $ 6,964     $ 8,539  
                 

Earnings Per Share of Common Stock:

               

Basic Earnings Per Share

  $ 0.28     $ 0.34  

Diluted Earnings Per Share

  $ 0.28     $ 0.34  
                 

Weighted average shares and share equivalents outstanding

Basic

    24,585       25,251  

Diluted

    24,738       25,390  

 

 

NRC Announces First Quarter 2023 Results

Page 4

May 2, 2023

 

 

NATIONAL RESEARCH CORPORATION AND SUBSIDIARY

Unaudited Condensed Consolidated Balance Sheets

(Dollars in thousands, except share amounts and par value)

 

   

March 31,

2023

   

December 31,

2022

 

Assets

               

Current assets:

               

Cash and cash equivalents

  $ 23,724     $ 25,026  

Accounts receivable, net

    14,220       14,461  

Other current assets

    7,228       4,229  

Total current assets

    45,172       43,716  
                 

Property and equipment, net

    19,486       17,248  

Goodwill

    61,614       61,614  

Other, net

    8,034       7,883  

Total assets

  $ 134,306     $ 130,461  
                 

Liabilities and Shareholders Equity

               

Current liabilities:

               

Current portion of notes payable

  $ 4,546     $ 4,491  

Accounts payable and accrued expenses

    5,193       5,136  

Accrued compensation

    4,977       4,551  

Deferred revenue

    15,896       15,198  

Dividends payable

    2,953       2,956  

Other current liabilities

    2,547       1,085  

Total current liabilities

    36,112       33,417  
                 

Notes payable, net of current portion and unamortized debt issuance costs

    16,530       17,690  

Other non-current liabilities

    6,999       7,321  

Total liabilities

    59,641       58,428  
                 

Shareholders’ equity:

               

Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued

    -       -  

Common stock, $0.001 par value; authorized 110,000,000 shares, issued 30,943,119 in 2023 and 30,922,181 in 2022, outstanding 24,599,815 in 2023 and 24,628,173 in 2022

    31       31  

Additional paid-in capital

    176,057       175,453  

Retained earnings (accumulated deficit)

    (21,173

)

    (25,184

)

                 

Treasury stock

    (80,250

)

    (78,267

)

Total shareholders’ equity

    74,665       72,033  

Total liabilities and shareholders’ equity

  $ 134,306     $ 130,461